QTTB vs AKRO vs IMVT vs ARQT vs CABA vs JPM

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). Q32 Bio Inc. (QTTB) offers the better valuation at 5. 2x trailing P/E, making it the more compelling value choice. Analysts rate Akero Therapeutics, Inc. (AKRO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Q32 Bio Inc.

(QTTB) is the cheapest at 5. 2x versus JPMorgan Chase & Co. at 15. 6x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +207. 0%, compared to -90. 2% for Q32 Bio Inc. (QTTB). Over 10 years, the gap is even starker: JPM returned +454. 4% versus QTTB's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Akero Therapeutics, Inc.

(AKRO) is the lower-risk stock at 0. 32β versus Cabaletta Bio, Inc. 's 2. 18β — meaning CABA is approximately 574% more volatile than AKRO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Q32 Bio Inc. grew EPS 136. 8% year-over-year, compared to -29. 8% for Akero Therapeutics, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Q32 Bio Inc.

(QTTB) is the more profitable company, earning 55. 5% net margin versus -4. 3% for Arcutis Biotherapeutics, Inc. — meaning it keeps 55. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QTTB leads at 31. 5% versus -3. 3% for ARQT. At the gross margin level — before operating expenses — QTTB leads at 99. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, JPMorgan Chase & Co.

(JPM) trades at 14. 1x forward P/E versus 123. 5x for Arcutis Biotherapeutics, Inc. — 109. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CABA: 442. 5% to $16. 33.

In this comparison, JPM (1.

9% yield) pays a dividend. QTTB, AKRO, IMVT, ARQT, CABA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), 1. 9% yield, +454. 4% 10Y return). Cabaletta Bio, Inc. (CABA) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +454. 4%, CABA: -69. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (QTTB (Healthcare) and AKRO (Healthcare) and IMVT (Healthcare) and ARQT (Healthcare) and CABA (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: QTTB is a small-cap deep-value stock; AKRO is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; CABA is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while QTTB, AKRO, IMVT, ARQT, CABA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.